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INTRODUCTION
Cervical cancer is the second most common cancer
found in women worldwide, and contributes to the
highest mortality rate among gynecological cancer.1
In 2002, approximately 493.000 new cases were di-
agnosed, and 83% of them were found in developing
countries.2 The prevalence of cervical cancer in Indo-
nesia is 100 - 190 per 100.000 citizen.3 Pathological
and surgical data in 2002 from 11 pathology centers
in Indonesia showed that cervical cancer is the most
Abstract
Objective: To evaluate clinical value of p16INK4a biomarker
level, by doing p16INK4a immunocytochemistry staining, as a pre-
dictor of progressivity of precancerous cervical lesion.
Method: Design of this research is case-control study which will
be stratified. Research was conducted in Cytology Laboratorium,
Gynecology Specialistic Division, Department of Obstetrics and
Gynecology, Dr. Cipto Mangunkusumo Hospital from August 2007
to September 2008. Immunocytochemistry examination was con-
ducted in Anatomic Pathology Department, Dr. Hasan Sadikin Hos-
pital. We divided the sample into two categories; patients with and
without cervical intraepithelial neoplasia (CIN). This research will
evaluate HPV infection and p16INK4a biomarker by doing p16INK4a
immunocytochemistry (ICC) staining.
Results: We have done immunocytochemistry examination in
130 patients, 26 without CIN and 104 with CIN. Immunocytoche-
mistry cut-off point level is 50, which means value < 50 means low
(L) p16INK4a expression and in reverse, value ≥ 50 means high (H)
p16INK4a  expression. The bivariate analysis of our study were
p16INK4a (H) expression has the risk of CIN 1 with OR 8.4, for CIN
2 with OR 13 and for CIN 3 with OR 21, greater than p16INK4a (L)
with all p values are significant. ICC p16INK4a (H) expression, age,
number of sexual partners, and education are contributory to the risk
of progressivity in CIN. The multivariate analysis demonstrates,
ICC expression of p16INK4a (H) has a risk (OR) of CIN 1 17.19
times greater than p16INK4a (L); p16INK4a (H) expression’s OR for
CIN 2 is 25.56; and for OR CIN 3 is 37.32. The expression of
p16INK4a has a significant p value and high OR, thus ICC expression
of p16INK4a is suggested to be included in the algorithm of pre-
cancerous cervical lesion guidelines and scoring of probability of
CIN as an alternative to HPV DNA considering less cost of the test.
In this research, we found a scoring model to determine probability
of progressivity in precancerous cervical lesion.
Conclusion: The expression of p16INK4a has a diagnostic value
in predicting the progressivity of precancerous cervical lesion.
[Indones J Obstet Gynecol 2010; 34-3: 125-30]
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Abstrak
Tujuan: Untuk mengevaluasi nilai klinis ekspresi biomarker
p16INK4a dengan pemeriksaan imunositokimia (ISK) sebagai faktor
prediktor progresivitas lesi prakanker serviks.
Metode: Desain penelitian ini adalah studi kasus-kontrol yang
akan dilakukan stratifikasi / tes dosis respon. Penelitian dilakukan
di Poliklinik Kolposkopi dan Laboratorium Sitologi, Divisi Gine-
kologi Spesialistik, Departemen Obstetri dan Ginekologi, RSUPN
Dr. Cipto Mangunkusumo, Jakarta. Penelitian berlangsung Agustus
2007 sampai September 2008. Pemeriksaan ISK dilakukan di Labo-
ratorium Patologi Anatomi RS Dr. Hasan Sadikin, Bandung. Kami
mengkategorikan pasien menjadi 2 kelompok yaitu kelompok kasus,
yaitu pasien dengan NIS dan kelompok kontrol, yaitu pasien dengan
NIS negatif (non NIS). Penelitian ini akan mengevaluasi biomarker
p16INK4a dengan cara pemeriksaan imunositokimia p16INK4a.
Hasil: Dilakukan pemeriksaan ISK pada 130 pasien, 26 tanpa
NIS dan 104 dengan NIS. Nilai titik potong ekspresi ISK p16INK4a
yang didapatkan adalah 50, nilai ekspresi ISK p16INK4a < 50 berarti
ekspresi rendah dan sebaliknya ≥ 50, tinggi. Analisis bivariat me-
nunjukkan hasil yang serupa dengan analisis multivariat. Di mana
ekspresi ISK p16INK4a tinggi memiliki odds ratio (OR) 8,4 pada NIS
1, OR 13 pada NIS 2, dan OR 21 pada NIS 3. Analisis multivariat
menunjukkan temuan serupa, ekspresi p16INK4a tinggi memiliki OR
17,19 pada NIS 1, 25,56 pada NIS 2 dan OR 37,32 pada NIS 3, de-
ngan nilai p yang bermakna. Ekspresi ISK p16INK4a tinggi, usia,
jumlah pasangan seksual, dan pendidikan memiliki kontribusi ter-
hadap risiko progresivitas NIS, dan dibuat suatu model skoring un-
tuk menilai probabilitas progresivitas pada lesi prakanker serviks.
Pemeriksaan ISK p16INK4a disarankan masuk ke dalam triase algo-
ritma penatalaksanaan lesi prakanker serviks (Atypical Squamous
Cells of Undertemined Significance dan Lesi Intraepitelial
Skuamosa Derajat Rendah) sebagai alternatif pilihan selain HPV
DNA dengan pertimbangan biaya yang lebih murah.
Kesimpulan: Perubahan ekspresi p16INK4a mempunyai kemam-
puan memprediksi progresivitas lesi prakanker serviks (NIS).
[Maj Obstet Ginekol Indones 2010; 34-3: 125-30]
Kata kunci: ekspresi imunositokimia p16INK4a, prediktor progre-
sivitas, lesi prakanker serviks
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common cancer, consisting of 23.54% among all can-
cers in men and women and 30.63% among ten most
prevalent cancers in women.4
Cervical cancer is a significant health problem in
Indonesia due to the fact that most cervical cancer
patient (62%) are presented with late stages.5 Cervical
cancer is a slow growing disease, which takes 5 - 20
years from carcinoma in situ to develop into cancer.6
Pap smear has dramatically reduced the incidence
of cervical cancer in countries where women has ac-
cess to cervical cytology examination facilities and
further treatment of malignant diseases. Around 50%
of cervical cancer cytological findings were unde-
tected in the first specimen evaluation and 40% of
cervical cancer was diagnosed in women who has pre-
viously received a negative test result.7 In developing
countries, it was estimated that only 5% of women
have had Pap smear evaluation, including in Indone-
sia.1,8 These women expect an evaluation with high
accuracy to avoid the relatively high rate of false
negatives in Pap smear result (10 - 50%)9, thus a new
examination to increase accuracy is needed.
Worldwide, 50 - 60% women have had HPV in-
fection in her lifetime, however only 10 - 20% of the
infection became persistent and contributed to the de-
velopment of high degree precancerous cervical lesion
or cervical cancer.8
The advance of cervical carcinogenetic detection
as molecular changes due to HPV infection has
opened a path for potential biomarkers to use as a
mediator in identifying diseases associated by HPV
infection in epithelial cells.10 These biomarkers could
one day have an important role in detection lesions
with potential progressivity and also contributes in
increasing the sensitivity of diagnostic procedures
available today.
Using liquid-based cytology specimens, p16INK4a
immunocytochemistry analysis has a higher Positive
Predictive Value than reflex HC2 HPV testing for
identifying CIN2/3 among patients with LSIL and
might be useful for selecting patients with LSIL for
colposcopy.11
It is desired that the examination of this biomarker
profile could improve the accuracy of Pap smear
screening, especially in doubtful cases such as Atypi-
cal Squamous Cell Undetermined Significant (AS-
CUS) or low-grade squamous intraepithelial lesion
(LGSIL), in determining the most appropriate treat-
ment based on the triage or as a consideration for
CIN 1 cases, whether a more conservative or more
aggressive treatment. Aditionally, this biomarker test
could improve the accuracy of cytology specimen
screening or HPV DNA test. A potential biomarker
currently studied is the p16INK4a.
In cervical dysplasia and cancer, increased produc-
tion of p16INK4a protein may be associated with the
degree of dysplasia demonstrated on a liquid-based speci-
men with immunocytochemical smear. The p16INK4a
is also suggested to be a more sensitive marker than
HPV DNA and p16INK4a is currently the most prom-
ising mediator biomarker of cervical dysplasia.12
Protein p16INK4a is a tumor suppressor protein
which acts as a CDK inhibitor. It is encoded by
CDKN2A located in chromosome 9 p 21. In dysplasia
and cervical cancer, increased production in protein
p16INK4a is related with the dysplastic degree that can
be seen in immunohistochemistry (IHC) staining or
in liquid-based cytology. Protein p16INK4a is now
considered as a more sensitive screening method com-
pared to HPV DNA test. The overexpression of
p16INK4a in epithelial cells applies to all degree of
dysplasia.13
HPV infection are characterized by expression of
the viral oncogen E6 and E7. Interference of the viral
oncogenes E6 and E7 with the apoptosis and cell cy-
cle regulator p53 and pRb in proliferating cells, result
in the induction of genomic instability. The inactiva-
tion of Rb as a result of deregulated HR-HPV E7 ex-
pression and the interaction of the E7 oncoprotein
with pRb pathway uniformly result in premature de-
gradation of the pRb complex.12
The pRb-E2F complex mediates the negative feed-
back for p16INK4a transcription. Alteration in pRb-
E2F complex by E7 releases p16INK4a gene from tran-
scription inhibition and results in over-expression of
p16INK4a gene.12
Some research have proven that low grade lesion
with a p16INK4a positive has progression risk higher
than lesion with p16INK4a negative. These research
show that p16INK4a can be used as a marker to dif-
ferentiate between a more progressive lesion and le-
sion that will spontaneously regress.14
The prognosis of a precancerous cervical lesion or
cervical cancer is generally differentiated in clinical
profile and histopathological profile. Although those
factors are considered or contributed in the disease’s
progressivity and prognosis, there are still other fac-
tors that couldn’t be differentiated clearly. Thus, a
biomarker profile is considered to make the distinc-
tion.15
The objective of this study is to determine the role
of biomarker p16INK4a by immunocytochemistry on
the progressivity of precancerous cervical lesion in
patients with HPV infections.
METHOD
The study design is case-control. There were 130 pa-
tients presented to Colposcopy Clinic Obstetrics and
Gynecology Department in Dr. Cipto Mangunkusumo
National Hospital, Jakarta who met the inclusion cri-
teria, admitted to the study. The CIN case group con-
sists of 104 patients and the non-CIN control group
consists of 26 patients.
The inclusion criteria for the case group includes:
18 - 50 years of age; have had sexual intercourse; and
histological CIN (+) from biopsy. The inclusion cri-
teria for the control group includes: 18 - 50 years of
age; have had sexual intercourse; and histological
CIN (–) from biopsy. The exclusion criteria for both
groups are pregnancy. These patients were selected
by Pap smear and target biopsy result (in accordance
to study guidelines).
ICC smear for p16INK4a was conducted in the La-
boratorium of Pathology Anatomy, Dr. Hasan Sadi-
kin Hospital, Bandung. There were 123 patients who
were eligible to undertake this examination. Seven pa-
tients were excluded because 4 patients had inconclu-
sive results and 3 patients had less or too few cells
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to examine. The p16INK4a expression was detected by
using a primer for mouse monoclonal anti-p16INK4a
antibody 2D9A12, Abcam ab54210 (Abcam Cam-
bridge UK). Semiquantitative ICC assessment was
conducted by 2 anatomy pathologists specializing in
this field. The p16INK4a expression is positive if a
dark brown stain was present in the nucleus with or
without cytoplasmic staining, with subsequent assess-
ment for intensity and distribution.
Statistical analysis was conducted using the soft-
ware Stata version 9.2. Analysis started as univariate
to determine the distribution of demographic, risk fac-
tor, and p16INK4a expression frequencies. Bivariate
analysis was used to determine the distribution of free
variables frequency and was associated with CIN pro-
gressivity, which was represented by Odds Ratio
(OR). The next step is using the multinomial logistic
regression analysis to design the best stepwise multi-
variate logistic regression model by including the
variable which has p value < 0.25.
Categorization is based on value limit, by calculat-
ing the cut-off points (COP) for demographic factors
(such as age, educational status, parity), risk factors
(number of sexual partners, first sexual intercourse,
oral contraception, smoking, and sexually transmitted
infection), and p16INK4a expression in ICC examina-
tions. The p16INK4a expression is considered low if
<COP and likewise ≥ COP is considered high. Before
calculating the scoring system, data input was per-
formed beforehand, due to several incomplete data in
some variables.
RESULTS
The data for demographic and risk factors were col-
lected compeletely from 130 patients. Subsequently,
data input for p16INK4a expression by ICC was per-
formed. The number of patients with CIN 1 was 33,
CIN 2 was 41, and CIN 3 was 30, with 26 patients
as control. Immunocytochemical evaluation of p16INK4a
was performed for these patients.
Based on the calculation of COP, the COP value
for each variable is as follows:
1. Age < 41 years old
2. Education ≥ 13 years
3. Parity ≥ 2
4. Number of sexual partners ≥ 2
5. First sexual intercourse < 22 years of age
6. p16INK4a expression ≥ 50
Table 1 demonstrates the data distribution of the
subject of this study based on the characteristic of
ICC p16INK4a expression, in which 47 patients were
categorized as low (L) p16INK4a expression, whereas
83 were high (H).
Table 1. Subjects Distribution Based on Immunocytochemistry
Immunocytochemistry
Expression Characteristics
n = 130
n %
p16INK4a
L (< 50) 47 36.15
H (≥ 50) 83 63.85
Note: H = high expression, L = low expression.
p16INK4a expression value = intensity x distribution
Table 2 shows that immunocytochemistry expres-
sion of p16INK4a (H) has the risk (OR) of CIN 1 8.4
times compared to p16INK4a (L) [95% CI, OR 2.49;
28.3 and p value = 0.001]. Whereas the risk of CIN
2, ICC expression of p16INK4a (H) has 13 times than
the risk of p16INK4a (L) [95% CI OR: 3.89; 43.56 and
p value = 0.0001] and for CIN 3 is 21 times [95%
CI OR: 5.34; 82.53, p value < 0.0001].
Table 3 demonstrates the progressivity prediction
model (fit model). For CIN 1, ICC p16INK4a (H) ex-
pression OR 15.91, p = 0.001; age OR 19.23, p =
0.0001; sexual partners OR 2.34, p = 0.394; education
OR 3.01, p = 0.208 are contributory to the risk of
progressivity in (CIN). In CIN 2 ICC expression of
p16INK4a (H) OR 30.82, p = 0.0001; age OR 17.81,
p = 0.001; sexual partners OR 7.92, p = 0.037, edu-
cation OR 6.25, p = 0.066 are at risk for CIN pro-
gressivity. In CIN 3 ICC expression of p16INK4a (H)
OR 40.34, p = 0.0001; age OR 12.87, p = 0.003; sex-
ual partners OR 5.57, p = 0.089, education OR 2.39,
p = 0.415 are all contributory to the risk of CIN.
Table 2. Odds Ratio and P value for CIN according to ICC p16INK4a expression characteristics.
ICC Expression
Characteristics
Non-CIN
n (%)
CIN 1
n (%)
OR (95%CI)
p value
CIN 2
n (%)
OR (95%CI)
p value
CIN 3
n (%)
OR (95%CI)
p value
p16INK4a
L (< 50) 21 (80.77) 11 (33.33) 1 10 (24.39) 1  5 (16.67) 1
H (≥ 50)  5 (19.23) 22 (66.67) 8.4 (2.49; 28.29) 31 (75.61) 13 (3.89; 43.57) 25 (83.30) 21 (5.34; 82.53)
Test for trend
(Chi2, p Value)
29.93 0.000 0.001 0.000 0.000
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Table 4 shows the probability of CIN with ICC
evaluation. The probability of CIN for patients with
scores 1 - 8 is the highest, which is 62.50%. For pa-
tients wih scores ≥ 9, the probability of CIN 2/CIN
3 is 91.67%.
Table 4. Probability of CIN with Evaluation of ICC p16INK4a
expression.
Score Non CIN CIN 1 CIN 2+3
0 100    0    0   
1 - 8   1.79 62.50 35.71
≥ 9   2.08  6.25 91.67
Table 3. The prediction model of CIN with the evaluation of ICC p16INK4a expression.
Variable coef SE coef coef/SE coef OR (95%CI OR) p value Score
CIN 1
p16INK4a 2.767 0.800 3.460 15.91 (3.32; 76.27) 0.001 4
Age 2.957 0.813 3.637 19.23 (3.91; 94.63) 0.000 4
Sexual Partner 0.851 1.000 0.852  2.34 (0.33; 16.62) 0.394 1
Education 1.100 0.994 1.107  3.01 (0.43; 21.07) 0.268 1
Constant -2.824 0.761 -3.710 0.000
CIN 2
p16INK4a 3.428 0.834 4.110 30.82 (6.01; 158.05) 0.000 5
Age 2.880 0.841 3.426 17.81 (3.43; 92.55) 0.001 4
Sexual Partner 2.069 0.990 2.090  7.92 (1.14; 55.13) 0.037 3
Education 1.833 0.997 1.839  6.25 (0.89; 44.12) 0.066 2
Constant -3.616 0.850 -4.253 0.000
CIN 3
p16INK4a 3.697 0.870 4.247 40.34 (7.32; 222.18) 0.000 5
Age 2.555 0.848 3.014 12.87 (2.44; 67.75) 0.003 4
Sexual Partner 1.718 1.011 1.698  5.57 (0.77; 40.45) 0.089 2
Education 0.872 1.069 0.816  2.39 (0.29; 19.42) 0.415 1
Constant -3.543 0.867 -4.085 0.000
Form 1. Scoring for the Prediction of CIN with Evaluation of ICC p16INK4a expression.
Variable (KI) CIN 1
(I)
Score
(KI x I)
(KI) CIN 2
(I)
Score
(KI x I)
(KI) CIN 3
(I)
Score
(KI x I)
ICC p16INK4a
Expression (L) 0 0 0
Expression (H) 1 4 1 5 1 5
Age
≥ 41 y.o 0 0 0
< 41 y.o 1 4 1 4 1 4
Sexual Partners
< 2 0 0 0
≥ 2 1 1 1 3 1 2
Education
< 13 years 0 0 0
≥ 13 years 1 1 1 2 1 1
Total Score
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DISCUSSION
The standard practice guidelines states that, ideally an
abnormal Pap smear result of a patient is followed by
a colposcopic examination for target biopsy, due to
the fact that definitive therapy is undertaken after a
histopathological result is obtained.
The treatment is based on ASCUS LG-SIL Triase
Study (ALTS) for cases with the Pap smear results
including ASCUS and LGSIL based on the American
Society of Colposcopy and Cervical Pathology (AS-
CCP) guidelines is either conducting a follow-up test
4 - 6 months later, HPV DNA detection, or colpos-
copic evaluation.
Thus, by conducting immunocytochemistry evalua-
tion of p16INK4a biomarker after the histopathological
result came out, a more precise decision for the next
treatment can be made, whether it is a conservative
treatment, which is follow-up, or colposcopy. If the
result of p16INK4a biomarker is known for CIN 1 pa-
tient, the score and probability of lesion progressivity
could be determined, which could lead to a more ac-
curate treatment decision. Although the cost is rela-
tively higher for conducting this test, the treatment
decision is more accurate either before or after a bi-
opsy result is obtained. Moreover, this biomarker eva-
luation is expected to replace HPV DNA evaluation
with a higher specificity.
A study by Bibbo et al on cervical swab used liquid-
based cytology suggested strong cytoplasmic staining
on low degree squamous intraepithelial lesion is
73.68%, whereas for high degree squamous intraepi-
thelial lesion is 96.15%. This is consistent with our
study, which shows the ICC expression of p16INK4a
(H) in CIN 1 is 66.67%, 75.61% for CIN 2, and
83.30% for CIN 3.16
In bivariate analysis of our study, ICC expression
of p16INK4a(H) compared with (L) p16INK4a had a
consistently increasing risk (OR) for the occurence of
CIN 1, CIN 2, and CIN 3 with p value < 0.01. This
was in line with the study by Branca et al17, which
in bivariate analysis found OR of IHC expression
p16INK4a on CIN 2 at 10.0 and on CIN 3 at 8.1, with
p value < 0.01.
Similarly, in multivariate analysis, we found the
ICC expression of (H) p16INK4a compared with (L)
p16INK4a had a consistently increasing risk for oc-
curence of CIN 1, CIN 2, and CIN 3. This is also in
line with the study conducted by Branca et al17, which
in multivariate analysis of IHC expression of p16INK4a
found adjusted OR for High Grade Squamous In-
traepithelial Lesion (HGSIL) at 4, with p value 0.001.
The higher the grade of CIN, the higher the ICC
expression of p16INK4a. This was consistent with
high-risk (HR) HPV infection in our study which
found an increase corresponding with the increase of
CIN grade. The role of E7 HR-HPV oncoprotein in
relation to the progression of CIN could be explain
in our study. Protein p16INK4a was a cdk inhibitor
protein which would inhibit the binding of cyclin and
cdk in which binding was necessary for phosphorilat-
ing pRB binding with E2F, such that E2F as the tran-
scription factor was released and would active cell
cycle. In condition in which there was HR-HPV in-
fection, there would be deregulation of cell cycle be-
cause E7 HR-HPV oncoprotein would bind pRb such
that E2F released and uncontrolled proliferation would
occur. On the other hand, in the condition in which
pRb is not active, there would be an increase of p16INK4a
through the negative feedback mechanism, and the in-
hibition of promoter p16INK4a would dissapear such
that an overexpression of p16INK4a would occur.
We found a predictive model for the progression,
there were 4 variables included into this model. If a
score 1 – 8 was found, the probability of CIN 1 would
be the highest, i.e., 62.50%. If the score was ≥ 9, the
probability for the occurence of CIN 2/CIN 3 was
91.67%.
The expression of p16INK4a has a significant p
value and high OR, thus ICC expression of p16INK4a
is included in the algorithm of cervical precancerous
cervical lesion guideline.
ASCUS/LGSIL (CIN I HPV) / 
ICC p16  examinationINK4a
4 - 6 mo Pap’s test
follow-up
Pap’s test result
HGSIL
( + ) ( – )
Colposcopy
Colposcopy
I
4 - 6 mo Pap’s test
follow-up
VI A  result
VI A  ( – )
( + ) ( – )
1yr VI A test follow-up
Colposcopy
VI A  (  )+
ICC p16  examinationINK4a
II
Note:
1. LGSIL: Low Grade Squamous Intraephitelial Lesion
2. HGSIL: High Grade Squamous Intraephitelial Lesion
Figure 1. The Algorithm of p16INK4a Role in CIN Guideline
Based on Abnormal Pap Smear Result (I) and Positive Visual
Inspection with Acetic Acid (VIA) (II)
Vol 34, No 3 |
July 2010 The progressivity of precancerous cervical lesion  129
|
RESULT
Patients aged < 41 years, ≥ 13 years length of edu-
cation, first time sexual intercourse < 22 years, ≥ 2
sexual partners and ICC p16INK4a high expression are
risk factors for CIN progressivity and they can be pre-
sumed as predictors.
There is a correlation between the level of p16INK4a
expression with the progression of cervical precancer
lesions (CIN). The higher the CIN grade, the higher
the p16INK4a expression presentation and the OR in-
creases.
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